Results 31 to 40 of about 77,108 (288)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors [PDF]

, 2019
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium ...
Au, L, Chauhan, D, Edmonds, K, Gore, M, Hughes, P, Husson, O, Lai, Z, Larkin, J, Lingard, K, Ludlow, A, Lynch, J, Mann, J, Mclean, E, O'Reilly, A, Pattison, N, Teh, JJ, Turajlic, S, Wiseman, T   +17 more
core   +3 more sources

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Acute visual loss after ipilimumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher   +8 more
doaj   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Journal of Clinical Oncology, 2022
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD ...
J. Brahmer, Jong-Seok Lee, T. Ciuleanu, R. Bernabé Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, A. Płużański, J. Burgers, M. Mahave, Samreen Ahmed, A. Schoenfeld, L. Paz-Ares, M. Reck, H. Borghaei, K. O'Byrne, Ravi G. Gupta, J. Bushong, Li Li, S. Blum, Laura J. Eccles, S. Ramalingam   +23 more
semanticscholar   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Abstract Background Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer ...
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +2 more sources

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Clinical Cancer Research, 2023
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit ...
J. Larkin, M. Del Vecchio, M. Mandalà, H. Gogas, A. Arance, S. Dalle, C. Cowey, M. Schenker, J. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, M. Butler, Anna Maria Di Giacomo, M. Middleton, J. Lutzky, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. Fecher, M. Millward, P. Nathan, N. Khushalani, P. Queirolo, C. Ritchings, M. Lobo, M. Askelson, Hao Tang, S. Dolfi, P. Ascierto, J. Weber   +30 more
semanticscholar   +1 more source

Ipilimumab: its potential in non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2012
Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is ...
Pascale Tomasini, Nataliya Khobta, Laurent Greillier, Fabrice Barlesi   +3 more
doaj   +1 more source